Recent Analysts’ Ratings Changes for Esperion Therapeutics (ESPR)

Several analysts have recently updated their ratings and price targets for Esperion Therapeutics (NASDAQ: ESPR):

  • 11/7/2018 – Esperion Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/6/2018 – Esperion Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
  • 11/1/2018 – Esperion Therapeutics was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 10/29/2018 – Esperion Therapeutics was upgraded by analysts at Northland Securities from a “market perform” rating to an “outperform” rating. They now have a $65.00 price target on the stock.
  • 10/26/2018 – Esperion Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/26/2018 – Esperion Therapeutics was given a new $82.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 10/19/2018 – Esperion Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/16/2018 – Esperion Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $82.00 price target on the stock.
  • 10/3/2018 – Esperion Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $51.00 price target on the stock. According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
  • 10/2/2018 – Esperion Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/22/2018 – Esperion Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/14/2018 – Esperion Therapeutics is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $89.00 price target on the stock.

NASDAQ:ESPR traded down $4.54 during mid-day trading on Friday, hitting $53.92. 41,241 shares of the company’s stock were exchanged, compared to its average volume of 998,075. Esperion Therapeutics Inc has a fifty-two week low of $33.06 and a fifty-two week high of $82.68. The company has a market cap of $1.58 billion, a PE ratio of -7.72 and a beta of 2.20.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.64) by ($0.22). During the same period last year, the business posted ($1.86) EPS. On average, equities analysts predict that Esperion Therapeutics Inc will post -6.48 earnings per share for the current fiscal year.

In other news, major shareholder Boxer Capital, Llc sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $55.21, for a total value of $2,208,400.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Roger S. Newton sold 9,400 shares of the business’s stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $50.01, for a total transaction of $470,094.00. Following the completion of the transaction, the director now owns 589,326 shares in the company, valued at approximately $29,472,193.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 177,327 shares of company stock worth $9,732,065. 32.50% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ESPR. Opera Trading Capital acquired a new position in shares of Esperion Therapeutics in the 3rd quarter worth approximately $173,000. Xact Kapitalforvaltning AB acquired a new position in shares of Esperion Therapeutics in the 1st quarter worth approximately $250,000. Keybank National Association OH lifted its position in shares of Esperion Therapeutics by 97.7% in the 2nd quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 3,787 shares during the period. Metropolitan Life Insurance Co. NY lifted its position in shares of Esperion Therapeutics by 40.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 2,224 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Esperion Therapeutics in the 2nd quarter worth approximately $333,000.

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Further Reading: How to Profit and Limit Losses With Stop Orders

Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply